| Mrs Lida Miller Oxnard, MD | |
|
809 Morton Ave Ste 200, Suite 200, Bardstown, KY 40004-2565 | |
| (502) 331-0411 | |
| (502) 331-0380 |
| Full Name | Mrs Lida Miller Oxnard |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 35 Years |
| Location | 809 Morton Ave Ste 200, Bardstown, Kentucky |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487738944 | NPI | - | NPPES |
| 000000052168 | Other | KY | ANTHEM |
| 64283120 | Medicaid | KY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 28312 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hardin Memorial Hospital | Elizabethtown, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Baptist Health Medical Group Inc | 5597867184 | 1912 |
News Archive
Magellan Health Services Inc. today reported financial results for the second quarter 2013, as summarized below. For the quarter ended June 30, 2013, the company reported net revenue of $842.7 million, segment profit of $75.0 million, and net income of $31.5 million or $1.15 per diluted common share.
In a first-of-its-kind study, Medical College of Georgia researchers are testing whether simulation driving can reduce Parkinson's patients' threefold increased risk of car accidents.
Human pluripotent stem cells, which can become any other kind of body cell, hold great potential to treat a wide range of ailments, including Parkinson's disease, multiple sclerosis and spinal cord injuries. However, scientists who work with such cells have had trouble growing large enough quantities to perform experiments - in particular, to be used in human studies. Furthermore, most materials now used to grow human stem cells include cells or proteins that come from mice embryos, which help stimulate stem-cell growth but would likely cause an immune reaction if injected into a human patient.
Regeneron Pharmaceuticals, Inc. today announced that the Company has entered into a non-exclusive license and partial settlement agreement with Genentech, Inc., a member of the Roche Group relating to U.S. ophthalmic sales of EYLEA (aflibercept) Injection.
› Verified 1 days ago
| Entity Name | Carefirst Urgent Care Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699725234 PECOS PAC ID: 5193753176 Enrollment ID: O20050801000383 |
News Archive
Magellan Health Services Inc. today reported financial results for the second quarter 2013, as summarized below. For the quarter ended June 30, 2013, the company reported net revenue of $842.7 million, segment profit of $75.0 million, and net income of $31.5 million or $1.15 per diluted common share.
In a first-of-its-kind study, Medical College of Georgia researchers are testing whether simulation driving can reduce Parkinson's patients' threefold increased risk of car accidents.
Human pluripotent stem cells, which can become any other kind of body cell, hold great potential to treat a wide range of ailments, including Parkinson's disease, multiple sclerosis and spinal cord injuries. However, scientists who work with such cells have had trouble growing large enough quantities to perform experiments - in particular, to be used in human studies. Furthermore, most materials now used to grow human stem cells include cells or proteins that come from mice embryos, which help stimulate stem-cell growth but would likely cause an immune reaction if injected into a human patient.
Regeneron Pharmaceuticals, Inc. today announced that the Company has entered into a non-exclusive license and partial settlement agreement with Genentech, Inc., a member of the Roche Group relating to U.S. ophthalmic sales of EYLEA (aflibercept) Injection.
› Verified 1 days ago
| Entity Name | Hardin Professional Services, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306894704 PECOS PAC ID: 9739191628 Enrollment ID: O20060614000061 |
News Archive
Magellan Health Services Inc. today reported financial results for the second quarter 2013, as summarized below. For the quarter ended June 30, 2013, the company reported net revenue of $842.7 million, segment profit of $75.0 million, and net income of $31.5 million or $1.15 per diluted common share.
In a first-of-its-kind study, Medical College of Georgia researchers are testing whether simulation driving can reduce Parkinson's patients' threefold increased risk of car accidents.
Human pluripotent stem cells, which can become any other kind of body cell, hold great potential to treat a wide range of ailments, including Parkinson's disease, multiple sclerosis and spinal cord injuries. However, scientists who work with such cells have had trouble growing large enough quantities to perform experiments - in particular, to be used in human studies. Furthermore, most materials now used to grow human stem cells include cells or proteins that come from mice embryos, which help stimulate stem-cell growth but would likely cause an immune reaction if injected into a human patient.
Regeneron Pharmaceuticals, Inc. today announced that the Company has entered into a non-exclusive license and partial settlement agreement with Genentech, Inc., a member of the Roche Group relating to U.S. ophthalmic sales of EYLEA (aflibercept) Injection.
› Verified 1 days ago
| Entity Name | Baptist Health Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740586213 PECOS PAC ID: 5597867184 Enrollment ID: O20070228000503 |
News Archive
Magellan Health Services Inc. today reported financial results for the second quarter 2013, as summarized below. For the quarter ended June 30, 2013, the company reported net revenue of $842.7 million, segment profit of $75.0 million, and net income of $31.5 million or $1.15 per diluted common share.
In a first-of-its-kind study, Medical College of Georgia researchers are testing whether simulation driving can reduce Parkinson's patients' threefold increased risk of car accidents.
Human pluripotent stem cells, which can become any other kind of body cell, hold great potential to treat a wide range of ailments, including Parkinson's disease, multiple sclerosis and spinal cord injuries. However, scientists who work with such cells have had trouble growing large enough quantities to perform experiments - in particular, to be used in human studies. Furthermore, most materials now used to grow human stem cells include cells or proteins that come from mice embryos, which help stimulate stem-cell growth but would likely cause an immune reaction if injected into a human patient.
Regeneron Pharmaceuticals, Inc. today announced that the Company has entered into a non-exclusive license and partial settlement agreement with Genentech, Inc., a member of the Roche Group relating to U.S. ophthalmic sales of EYLEA (aflibercept) Injection.
› Verified 1 days ago
| Entity Name | Baptist Health Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922401611 PECOS PAC ID: 5597867184 Enrollment ID: O20150219000942 |
News Archive
Magellan Health Services Inc. today reported financial results for the second quarter 2013, as summarized below. For the quarter ended June 30, 2013, the company reported net revenue of $842.7 million, segment profit of $75.0 million, and net income of $31.5 million or $1.15 per diluted common share.
In a first-of-its-kind study, Medical College of Georgia researchers are testing whether simulation driving can reduce Parkinson's patients' threefold increased risk of car accidents.
Human pluripotent stem cells, which can become any other kind of body cell, hold great potential to treat a wide range of ailments, including Parkinson's disease, multiple sclerosis and spinal cord injuries. However, scientists who work with such cells have had trouble growing large enough quantities to perform experiments - in particular, to be used in human studies. Furthermore, most materials now used to grow human stem cells include cells or proteins that come from mice embryos, which help stimulate stem-cell growth but would likely cause an immune reaction if injected into a human patient.
Regeneron Pharmaceuticals, Inc. today announced that the Company has entered into a non-exclusive license and partial settlement agreement with Genentech, Inc., a member of the Roche Group relating to U.S. ophthalmic sales of EYLEA (aflibercept) Injection.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Lida Miller Oxnard, MD 809 Morton Ave, Suite 200, Bardstown, KY 40004-2565 Ph: (502) 331-0411 | Mrs Lida Miller Oxnard, MD 809 Morton Ave Ste 200, Suite 200, Bardstown, KY 40004-2565 Ph: (502) 331-0411 |
News Archive
Magellan Health Services Inc. today reported financial results for the second quarter 2013, as summarized below. For the quarter ended June 30, 2013, the company reported net revenue of $842.7 million, segment profit of $75.0 million, and net income of $31.5 million or $1.15 per diluted common share.
In a first-of-its-kind study, Medical College of Georgia researchers are testing whether simulation driving can reduce Parkinson's patients' threefold increased risk of car accidents.
Human pluripotent stem cells, which can become any other kind of body cell, hold great potential to treat a wide range of ailments, including Parkinson's disease, multiple sclerosis and spinal cord injuries. However, scientists who work with such cells have had trouble growing large enough quantities to perform experiments - in particular, to be used in human studies. Furthermore, most materials now used to grow human stem cells include cells or proteins that come from mice embryos, which help stimulate stem-cell growth but would likely cause an immune reaction if injected into a human patient.
Regeneron Pharmaceuticals, Inc. today announced that the Company has entered into a non-exclusive license and partial settlement agreement with Genentech, Inc., a member of the Roche Group relating to U.S. ophthalmic sales of EYLEA (aflibercept) Injection.
› Verified 1 days ago
Britta Zoeller Maciuba, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 201 S 5th St, Bardstown, KY 40004 Phone: 502-348-5968 | |
William Lawrence Hagan, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 201 S 5th St, Bardstown, KY 40004 Phone: 502-348-5968 Fax: 502-349-0963 | |
Hugh Hall Jr., M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 703 Mcdowell Blvd, Suite 100, Bardstown, KY 40004 Phone: 502-349-1212 Fax: 502-349-1216 | |
Mark Allan Abramovich, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 300 W John Fitch Ave, Suite 210, Bardstown, KY 40004 Phone: 502-348-7648 Fax: 502-348-7490 | |
Jacob William Vincent, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3615 E John Rowan Blvd Ste 104, Bardstown, KY 40004 Phone: 502-348-5968 Fax: 270-706-5802 | |
Matthew Abel, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3615 E John Rowan Blvd Ste 104, Bardstown, KY 40004 Phone: 502-348-5968 Fax: 270-706-5802 |